[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631886":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":20,"responsibleParty":27,"collaborators":20,"id":30,"slug":31,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":34,"acronym":35,"eligibilityCriteria":36,"healthyVolunteers":32,"sex":37,"minAge":20,"maxAge":20,"enrollmentInfo":38,"targetDuration":20,"studyType":41,"phases":42,"briefSummary":44,"conditions":45,"keywords":47,"overallStatus":50,"whyStopped":20,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":20},{"fullName":5,"class":6},"University of Pennsylvania","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Mifepristone and Misoprostol","EXPERIMENTAL","200mg oral mifepristone and 800mg vaginal misoprostol",[13],"Drug: 200mg mifepristone and 800mg misoprostol",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","200mg mifepristone and 800mg misoprostol","Participants will take 200mg of mifepristone by mouth and will be instructed to administer misoprostol any time between 4- and 24-hours post-mifepristone.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Courtney Schreiber","CONTACT","267-785-8044","peaceresearch@pennmedicine.upenn.edu",{"type":28,"investigatorFullName":23,"investigatorTitle":29,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Professor","100631886","phase-3-optimal-time-interval-between-mifepristone-and-misoprostol-administration-for-early-pregnancy-loss-100631886",false,"NCT07506512","Optimal Time Interval Between Mifepristone and Misoprostol Administration for Early Pregnancy Loss","TIME","Inclusion Criteria:\n\n* Able to participate in the informed consent process and provide a signed and dated consent form.\n* Stated willingness to comply with all study procedures.\n* Access to device with text or email capability.\n* Able to read and understand English.\n* Confirmed diagnosis of intrauterine embryonic\u002Ffetal demise or anembryonic gestation (ultrasound examination demonstrates a fetal pole without cardiac activity measuring between 5.3 and 40mm or an abnormal growth pattern diagnostic of early pregnancy loss.\n\nExclusion Criteria:\n\n* Incomplete or inevitable abortion.\n* Contraindication or allergy to mifepristone or misoprostol\n* Unable to return for clinic-based follow-up.","FEMALE",{"count":39,"type":40},1000,"ESTIMATED","INTERVENTIONAL",[43],"PHASE3","A prospective cohort study to explore the optimal time interval between mifepristone and misoprostol administration for medical management of early pregnancy loss. Participants will be followed to assess treatment success, satisfaction, and side effects.",[46],"Early Pregnancy Loss",[48,49],"early pregnancy loss","miscarriage","NOT_YET_RECRUITING","2026-03-26",{"date":53,"type":54},"2026-04-01","ACTUAL",{"date":56,"type":40},"2026-07",{"date":58,"type":40},"2031-12",{"name":5,"class":6}]